RTTNews | Oct 12, 2021 07:16AM EDT

07:16 Tuesday, October 12, 2021 (RTTNews.com) - Deciphera Pharmaceuticals, Inc. (DCPH) announced the Swiss Agency for Therapeutic Products or Swissmedic, has granted approval for QINLOCK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib.

"The approval in Switzerland is our seventh approval worldwide and the first in Europe," said Steve Hoerter, CEO of Deciphera. The company anticipates a potential approval from the European Commission for QINLOCK in the fourth quarter of the current year.

Read the original article on RTTNews ( https://www.rttnews.com/3232012/deciphera-pharma-reports-approval-of-qinlock-in-switzerland-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved